SEC Form 4 · accession 0000899243-17-005893
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David D Chang
Officer — EVP, R&D, Chief Medical Off.
Period of report
Mar 1, 2017
Accepted (ET)
Mar 2, 2017 · 6:08 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 1, 2017 | M | 60,000 | $6.89 | A | 110,165 | D | |
| Common StockF3 | Mar 1, 2017 | S | 55,265 | $79.11 | D | 54,900 | D | |
| Common StockF4 | Mar 1, 2017 | S | 4,735 | $79.71 | D | 50,165 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option(Right to Buy)F5 | $6.89 | Mar 1, 2017 | M | 60,000 | D | — | Jun 5, 2024 | Common Stock | 60,000 | 163,000 | D |
Explanation of responses
- F1Includes 242 shares acquired under the 2014 Employee Stock Purchase Plan on February 17, 2017.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.60 to $79.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.60 to $79.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F525% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.